APSR2026-717

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-013
P55
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221172-46904-Abstract 1 Poster_433493.pdf
Format: PDF Only
09. Asthma
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Diana-Leh Ching Ng - Universiti Malaysia Sarawak Department of Medicine, Faculty of Medicine and Health Science Kota Samarahan Malaysia
Norlia Bt Abdullah Abdul Rahman - Universiti Malaysia Sarawak Department of Medicine, Faculty of Medicine and Health Science Kota Samarahan Malaysia
Yen-Shen Wong - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Aisya Natasya Bt Musa - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Am Basheeri B Alias - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Syahrinnaquiah Bt Samsuddin - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Chee-Shee Chai * Universiti Malaysia Sarawak Department of Medicine, Faculty of Medicine and Health Science Kota Samarahan Malaysia
Chong-Kin Liam - Universiti Malaya Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia
 
 
 
 
 
 
 
Presenting Author Details
Chee-Shee
Chai
cheeshee1981@gmail.com
+60198188265
41-50
Malaysia
Original Research
Early asthma phenotyping reveals Th2 predominance and distinct clinical features: a cross-sectional study in Malaysia
Maximum 25 words
Abstract Content
GINA recommends phenotyping asthma into T helper type 2 (Th2) and non–Th2 primarily after inadequate response to Step 4 therapy. However, data on asthma phenotypes at initial diagnosis remain limited. This study aimed to determine the prevalence of Th2 and non–Th2 asthma at diagnosis and the associated clinical features.
This observational cross-sectional study was conducted from September 2023 to December 2025 at the respiratory specialist clinics of Universiti Malaysia Sarawak and Hospital Al-Sultan Abdullah, Malaysia. Adults aged ≥18 years with asthma and without other chronic lung diseases were included. Th2 asthma was defined by clinical allergic features, fractional exhaled nitric oxide (FeNO) >20 ppb, or blood eosinophils >150 cells/µL; others were classified as non–Th2. Data were analysed using descriptive and inferential statistics.
Among 165 patients, 123 (74.5%) had Th2 asthma and 42 (25.5%) had non–Th2 asthma. Within the Th2 group, 99 (80.5%) had clinically allergy-driven disease, 63 (51.2%) elevated FeNO, and 20 (16.2%) raised eosinophils; with 41 (33.3%) reported identifiable allergens, mainly aeroallergens. Compared with non–Th2 patients, Th2 patients were younger (44.1 ± 15.8 vs 50.2 ± 15.8 years, p=0.034), more likely to have a first-degree family history of asthma (50.4% vs 31.0%, p=0.029), more frequently presented with dyspnoea/chest tightness (52.0% vs 33.0%, p=0.036) and sputum production (20.3% vs 2.4%, p=0.006), and had higher bronchodilator reversibility (31.7% vs 26.6%, p=0.013). No significant between group differences were observed in terms of gender, body mass index, smoking history, childhood asthma history, other respiratory symptoms, asthma pattern, symptom frequency, nocturnal awakening, asthma control test score, spirometry or impulse oscillometry indices.
Th2 asthma predominates at diagnosis, accounting for approximately three-quarters of cases. It is associated with younger age, stronger family history, and greater bronchodilator reversibility. Early phenotyping may facilitate more targeted management.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Bronchial asthma, phenotype, T helper type 2
maximum 3 keywords and no abbreviations, separated by commas
This study was supported by the Vice-Chancellor High Impact Research Grant Scheme of Universiti Malaysia Sarawak (UNI/F05/VC-HIRG/85478/P01-01/2022). The authors declare no conflicts of interest.
321